Amiad (AIM: AFS), a leading global producer of water treatment and filtration solutions, announces that it has allotted 16,463 ordinary shares of
NIS 0.5 each in the Company ( Ordinary Shares ) following the exercise of options by Noam Shlasky, Chief Operating Officer, VP Operations, and a person discharging managerial responsibilities (PDMR) of the Company.
Following the options exercise, Mr. Shlasky has an interest in 16,463 Ordinary Shares representing 0.05% of the Company s enlarged issued share capital.
Application has been made to the London Stock Exchange for 16,463 new Ordinary Shares to be admitted to trading on AIM ( Admission ) and it is expected that Admission will become effective and trading will commence at
+44 (0)20 7710 7600 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) Nick Adams / Fred Walsh (Corporate Broking) Walbrook PR Paul McManus / Anna Dunphy The Company and its wholly owned subsidiary, Polarean, Inc. (together the Group ) are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (
129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other
+44 (0)20 7710 7600 Nicholas Moore / Ben Maddison / Samira Essebiyea (Healthcare Investment Banking) Nick Adams / Fred Walsh (Corporate Broking) Walbrook PR Paul McManus / Anna Dunphy The Company and its wholly owned subsidiary, Polarean, Inc. (together the Group ) are revenue generating, medical drug-device combination companies operating in the high resolution medical imaging market. The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (
129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other
Avacta Group is developing novel cancer immunotherapies and powerful diagnostics based on its two proprietary platforms - Affimer® biologics and pre|CISION™ tumour targeted chemotherapies. The Affimer platform is an alternative to antibodies derived from a small human protein. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100bn. Affimer technology has been designed to address many of these negative performance issues, principally: the time taken to generate new antibodies and the reliance on an animal s immune response; poor specificity in many cases; their large size, complexity and high cost of manufacture. Avacta s pre|CISION targeted chemotherapy platform releases active chemotherapy in the tumour, which limits the systemic exposure that causes damage to healthy tissues, and thereby improves the overall safety and therapeutic potential of these pow
Investegate |Avacta Group PLC Announcements | Avacta Group PLC: Issue of Equity investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.